Bristol Myers’ CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market

Despite being third to the field in B cell lymphoma, Bristol Myers Squibb has repeatedly argued its CAR-T Breyanzi could have the juice to overtake its older competitors. Going into earlier lines of therapy may be the golden ticket on that front, and now Breyanzi has a late-stage win to...

Click to view original post